Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Arterial Thrombosis - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 21 Oct 16

Research and Markets has announced the addition of the "Arterial Thrombosis - Pipeline Review, H2 2016" report to their offering.

Arterial Thrombosis pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Arterial Thrombosis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Arterial Thrombosis Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin and coldness. Depending on where the clot forms, arterial thrombosis can cause several serious conditions, including stroke, heart attack and peripheral arterial disease (PAD).

Predisposing factors include smoking, obesity, diabetes, hypertension and high cholesterol level. Treatment includes thrombolytic agents and surgery. The molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Arterial Thrombosis Overview
  3. Therapeutics Development
  4. Pipeline Products for Arterial Thrombosis - Overview
  5. Pipeline Products for Arterial Thrombosis - Comparative Analysis
  6. Arterial Thrombosis - Therapeutics under Development by Companies
  7. Arterial Thrombosis - Therapeutics under Investigation by Universities/Institutes
  8. Arterial Thrombosis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Arterial Thrombosis - Products under Development by Companies
  13. Arterial Thrombosis - Products under Investigation by Universities/Institutes
  14. Arterial Thrombosis - Companies Involved in Therapeutics Development
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Johnson & Johnson
  • Sanofi
  • Thromboserin Ltd
  • TSRL, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 21/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.